GB-5267
Metastatic Ovarian Cancer
PreclinicalIND study may proceed (Dec 2025); 50/50 Collaboration
Key Facts
Indication
Metastatic Ovarian Cancer
Phase
Preclinical
Status
IND study may proceed (Dec 2025); 50/50 Collaboration
Company
About Generate Biomedicines
Generate Biomedicines is a Flagship Pioneering company on a mission to program biology, using its proprietary Generate Platform to create novel protein therapeutics with unprecedented speed and precision. The company achieved a significant validation milestone with its IPO in March 2026, raising capital to advance a diversified pipeline led by GB-0895, a long-acting anti-TSLP antibody now in global Phase 3 studies for severe asthma. Its strategy leverages a continuous learning loop that integrates computational design with high-throughput experimental validation, aiming to build a broad portfolio of internally developed and partnered programs across immunology, oncology, and beyond.
View full company profile